274 related articles for article (PubMed ID: 22970187)
21. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
[TBL] [Abstract][Full Text] [Related]
22. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.
Ma BJ; Alam SM; Go EP; Lu X; Desaire H; Tomaras GD; Bowman C; Sutherland LL; Scearce RM; Santra S; Letvin NL; Kepler TB; Liao HX; Haynes BF
PLoS Pathog; 2011 Sep; 7(9):e1002200. PubMed ID: 21909262
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
[TBL] [Abstract][Full Text] [Related]
24. Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail.
Samal S; Das S; Boliar S; Qureshi H; Shrivastava T; Kumar N; Goswami S; Bansal M; Chakrabarti BK
Retrovirology; 2018 Jul; 15(1):50. PubMed ID: 30029604
[TBL] [Abstract][Full Text] [Related]
25. Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.
Venditto VJ; Wieczorek L; Molnar S; Teque F; Landucci G; Watson DS; Forthal D; Polonis VR; Levy JA; Szoka FC
Clin Vaccine Immunol; 2014 Aug; 21(8):1086-93. PubMed ID: 24872518
[TBL] [Abstract][Full Text] [Related]
26. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
Tolbert WD; Nguyen DN; Tehrani ZR; Sajadi MM; Pazgier M
mBio; 2021 Aug; 12(4):e0127421. PubMed ID: 34281393
[TBL] [Abstract][Full Text] [Related]
27. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency.
Zhang MY; Dimitrov DS
Curr Pharm Des; 2007; 13(2):203-12. PubMed ID: 17269928
[TBL] [Abstract][Full Text] [Related]
28. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
Finnegan CM; Berg W; Lewis GK; DeVico AL
J Virol; 2002 Dec; 76(23):12123-34. PubMed ID: 12414953
[TBL] [Abstract][Full Text] [Related]
29. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign.
Tran K; Poulsen C; Guenaga J; de Val N; Wilson R; Sundling C; Li Y; Stanfield RL; Wilson IA; Ward AB; Karlsson Hedestam GB; Wyatt RT
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):E738-47. PubMed ID: 24550318
[TBL] [Abstract][Full Text] [Related]
30. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.
Falkowska E; Ramos A; Feng Y; Zhou T; Moquin S; Walker LM; Wu X; Seaman MS; Wrin T; Kwong PD; Wyatt RT; Mascola JR; Poignard P; Burton DR
J Virol; 2012 Apr; 86(8):4394-403. PubMed ID: 22345481
[TBL] [Abstract][Full Text] [Related]
31. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
[TBL] [Abstract][Full Text] [Related]
33. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
34. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
Gach JS; Quendler H; Tong T; Narayan KM; Du SX; Whalen RG; Binley JM; Forthal DN; Poignard P; Zwick MB
PLoS One; 2013; 8(8):e72054. PubMed ID: 23991039
[TBL] [Abstract][Full Text] [Related]
35. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
36. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
37. Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement.
Liu Q; Zhang P; Miao H; Lin Y; Kwon YD; Kwong PD; Rikhtegaran-Tehrani Z; Seaman MS; DeVico AL; Sajadi MM; Lusso P
J Virol; 2021 May; 95(12):. PubMed ID: 33827946
[TBL] [Abstract][Full Text] [Related]
38. Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.
Lu M; Ma X; Reichard N; Terry DS; Arthos J; Smith AB; Sodroski JG; Blanchard SC; Mothes W
J Virol; 2020 Aug; 94(17):. PubMed ID: 32522853
[TBL] [Abstract][Full Text] [Related]
39. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
Li Y; O'Dell S; Walker LM; Wu X; Guenaga J; Feng Y; Schmidt SD; McKee K; Louder MK; Ledgerwood JE; Graham BS; Haynes BF; Burton DR; Wyatt RT; Mascola JR
J Virol; 2011 Sep; 85(17):8954-67. PubMed ID: 21715490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
